Squamous cell carcinoma - 편평 세포암
☆ AI Dermatology — Free Service
2022년 독일의 Stiftung Warentest 결과에 따르면 ModelDerm에 대한 소비자 만족도는 유료 원격진료 상담보다 약간 낮았습니다.
2022년 독일의 Stiftung Warentest 결과에 따르면 ModelDerm에 대한 소비자 만족도는 유료 원격진료 상담보다 약간 낮았습니다.
편평 세포암 (Squamous cell carcinoma) ― 팔뚝
relevance score : -100.0%
ReferencesSquamous cell carcinoma (SCC)은 미국에서 basal cell carcinoma에 이어 두 번째로 흔한 피부암입니다. 대부분은 actinic keratosis라고 불리는 전암성 병변에서 시작하며, 신체의 다른 부위로 전이될 수 있습니다. 주요 원인은 시간이 지남에 따라 축적되는 태양의 자외선(UV) 방사선에 노출되는 것입니다. 치료는 일반적으로 수술적 제거가 포함되며, 특히 머리와 목에 발생한 SCC의 경우 더욱 그렇습니다. 방사선 치료는 고령 환자나 수술이 어려운 환자를 위한 옵션입니다. 면역억제는 SCC 위험을 증가시킵니다. 드물지만, 면역 체계가 약화된 환자에서는 SCC가 전이될 수 있습니다. SCC 환자는 정기적인 검진과 자외선 차단이 중요합니다.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC)은 사람에게 두 번째로 흔한 암이며, 그 발생 빈도가 증가하고 있습니다. CSCC는 일반적으로 양성 임상 양상을 보이지만, 국소적으로 혹은 신체의 다른 부위로 전이될 수 있습니다. 연구자들은 CSCC 발생과 관련된 특정 경로를 규명하여 새로운 치료법을 개발했습니다. 면역억제 환자에서 높은 돌연변이 수와 위험 증가가 면역요법 개발을 촉진했습니다. 이 리뷰에서는 CSCC의 유전적 근원과 특정 분자 및 면역 체계를 표적으로 하는 최신 치료법을 살펴봅니다.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ 진단 및 치료
#Dermoscopy
#Skin biopsy